Promising preclinical research suggests that ASDERA's investigatonal drug may reduce tumor growth and inflammation and prevent metastases in breast bancer and other epithelial cancers.

Women with triple-negative breast cancer have only few toxic treatment options. The patented ASDERA approach identified the mechanism under lying "derailed" endocytosis and a drug to "rerail" it. 

The proposed mechanism of action under investigation is up- regulation of endocytosis (of β1 integrin) and the proposed drug is an oral, intestinally absorbed compound of HP-α-cyclodextrin intended to down-regulates both the activity of the PI-cycle, which controls endocytosis, and also systemic inflammation

(click on either of the icons below to download a 2-page flyer pdf (left), a pdf deck (center) or the 2018 publication (right) with more details)